-
Je něco špatně v tomto záznamu ?
Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines
V. Králová, V. Hanušová, P. Staňková, K. Knoppová, K. Čáňová, L. Skálová,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
- MeSH
- adenokarcinom farmakoterapie MeSH
- albendazol analogy a deriváty farmakologie MeSH
- anthelmintika farmakologie MeSH
- antitumorózní látky fytogenní farmakologie MeSH
- antitumorózní látky farmakologie MeSH
- chemorezistence účinky léků MeSH
- G2 fáze účinky léků MeSH
- inhibiční koncentrace 50 MeSH
- lidé MeSH
- mebendazol analogy a deriváty farmakologie MeSH
- mikrotubuly účinky léků MeSH
- modulátory tubulinu farmakologie MeSH
- nádorové buněčné linie MeSH
- paclitaxel farmakologie MeSH
- proliferace buněk účinky léků MeSH
- stabilita proteinů účinky léků MeSH
- střevní nádory farmakoterapie MeSH
- synergismus léků MeSH
- viabilita buněk účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
This study aimed to test the antiproliferative effect of three benzimidazole anthelmintics in intestinal cancer cells and to investigate whether these drugs, which inhibit tubulin polymerization, can potentiate the efficacy of the microtubule-stabilizing drug paclitaxel (PTX). Four intestinal cancer cell lines, SW480, SW620, HCT8, and Caco2, with different origins and growth characteristics were used. The antiproliferative effect of albendazole (ABZ), ricobendazole (RBZ), flubendazole (FLU), and their combinations with PTX was tested using three different end-point viability assays, cell cycle distribution analysis, and the x-CELLigence System for real-time cell analysis. ABZ and FLU inhibited cell proliferation significantly in a concentration-dependent and time-dependent manner through cell arrest in the G2/M phase. RBZ was not effective at any concentration tested. The cell lines differed in sensitivity to FLU and ABZ, with HCT8 being the most sensitive, showing IC₅₀ values for ABZ and FLU that reached 0.3 and 0.9 μmol/l, respectively. Combinations of PTX+ABZ and PTX+FLU decreased cell viability more effectively when compared with treatment with individual drugs alone. The anthelmintic benzimidazole drugs ABZ and FLU show a significant cytostatic effect and potentiate the efficacy of PTX in intestinal cancer cells.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14050890
- 003
- CZ-PrNML
- 005
- 20140408110952.0
- 007
- ta
- 008
- 140401s2013 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/CAD.0b013e3283648c69 $2 doi
- 035 __
- $a (PubMed)23884106
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Králová, Věra
- 245 10
- $a Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines / $c V. Králová, V. Hanušová, P. Staňková, K. Knoppová, K. Čáňová, L. Skálová,
- 520 9_
- $a This study aimed to test the antiproliferative effect of three benzimidazole anthelmintics in intestinal cancer cells and to investigate whether these drugs, which inhibit tubulin polymerization, can potentiate the efficacy of the microtubule-stabilizing drug paclitaxel (PTX). Four intestinal cancer cell lines, SW480, SW620, HCT8, and Caco2, with different origins and growth characteristics were used. The antiproliferative effect of albendazole (ABZ), ricobendazole (RBZ), flubendazole (FLU), and their combinations with PTX was tested using three different end-point viability assays, cell cycle distribution analysis, and the x-CELLigence System for real-time cell analysis. ABZ and FLU inhibited cell proliferation significantly in a concentration-dependent and time-dependent manner through cell arrest in the G2/M phase. RBZ was not effective at any concentration tested. The cell lines differed in sensitivity to FLU and ABZ, with HCT8 being the most sensitive, showing IC₅₀ values for ABZ and FLU that reached 0.3 and 0.9 μmol/l, respectively. Combinations of PTX+ABZ and PTX+FLU decreased cell viability more effectively when compared with treatment with individual drugs alone. The anthelmintic benzimidazole drugs ABZ and FLU show a significant cytostatic effect and potentiate the efficacy of PTX in intestinal cancer cells.
- 650 _2
- $a adenokarcinom $x farmakoterapie $7 D000230
- 650 _2
- $a albendazol $x analogy a deriváty $x farmakologie $7 D015766
- 650 _2
- $a anthelmintika $x farmakologie $7 D000871
- 650 _2
- $a antitumorózní látky $x farmakologie $7 D000970
- 650 _2
- $a antitumorózní látky fytogenní $x farmakologie $7 D000972
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a chemorezistence $x účinky léků $7 D019008
- 650 _2
- $a synergismus léků $7 D004357
- 650 _2
- $a G2 fáze $x účinky léků $7 D016195
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inhibiční koncentrace 50 $7 D020128
- 650 _2
- $a střevní nádory $x farmakoterapie $7 D007414
- 650 _2
- $a mebendazol $x analogy a deriváty $x farmakologie $7 D008463
- 650 _2
- $a mikrotubuly $x účinky léků $7 D008870
- 650 _2
- $a paclitaxel $x farmakologie $7 D017239
- 650 _2
- $a stabilita proteinů $x účinky léků $7 D055550
- 650 _2
- $a modulátory tubulinu $x farmakologie $7 D050257
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hanušová, Veronika $u -
- 700 1_
- $a Staňková, Petra $u -
- 700 1_
- $a Knoppová, Kateřina $u -
- 700 1_
- $a Čáňová, Kristýna $u -
- 700 1_
- $a Skálová, Lenka $u -
- 773 0_
- $w MED00179775 $t Anti-cancer drugs $x 1473-5741 $g Roč. 24, č. 9 (2013), s. 911-9
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23884106 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140401 $b ABA008
- 991 __
- $a 20140408111040 $b ABA008
- 999 __
- $a ok $b bmc $g 1018026 $s 849470
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 24 $c 9 $d 911-9 $i 1473-5741 $m Anticancer Drugs $n Anticancer Drugs $x MED00179775
- LZP __
- $a Pubmed-20140401